

Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
December 24, 2024

Notice Regarding the Establishment of the Preparatory Committee for the Transfer of the Group Medical Wholesaling Business Management Department

On January 1, 2025, Alfresa Holdings Corporation will establish the Preparatory Committee for the Transfer of the Group Medical Wholesaling Business Management Department (hereinafter “the committee”). Details are as follows.

1. Timeline and Purpose of Establishment

On April 1, 2023, Alfresa Holdings Corporation established the Group Medical Wholesaling Business Management Department and the Medical Wholesaling Business Strategy Department, its subdepartment. Although the Company has since strengthened Groupwide governance in the Alfresa Group’s Ethical Pharmaceuticals Wholesaling Business, it has concluded that the further bolstering of functions is necessary. To that end, it has decided to establish the committee.

As of April 1, 2025, the committee will transfer the functions of the Group Medical Wholesaling Business Management Department to Alfresa Corporation, the Company’s largest subsidiary, and examine organizational restructuring and personnel strategy for the Group on the basis of strengthening governance in the Ethical Pharmaceuticals Wholesaling Business and further enhancing support functions.

2. Composition of the Committee

Chair	Yusuke Fukujin, Representative Director & President, Alfresa Corporation, Representative Director & Executive Vice President, Ethical Pharmaceuticals Wholesaling Business, Total Supply Chain Services, International Business, Alfresa Holdings Corporation
Members	Shigeki Ohashi, Director, Vice President & Executive Officer, General Manager of Group Ethical Wholesaling Business, Alfresa

	Holdings Corporation,
	Tadashi Yoshida, Director, Senior Vice President & Executive Officer, General Manager of Corporate Division, Alfresa Corporation

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: <https://www.alfresa.com/eng/>